Published in TB and Outbreaks Week, August 26th, 2003
No serious adverse events were reported.
Phase I testing evaluated the safety of vaccinia immune globulin in 33 healthy volunteers at a clinical research facility in Lenexa, Kansas. Each volunteer received a dose of 100 milligrams of vaccinia immune globulin per kilogram of body weight. There were no serious adverse events among the study...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week